Scholarlink

<p>Chronic kidney disease (CKD) is an emerging concern in the aging population of people living with HIV, especially in those with history of nephrotoxic antiretroviral therapy. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown renoprotective effects in various clinical settings, but their utility in patients with antiretroviral-induced kidney impairment remains unexplored. We report the case of a 59-year-old man with well-controlled HIV infection who developed progressive decline in estimated glomerular filtration rate (eGFR, mL/min/1.73 m<sup>2</sup>) over 15&#xa0;years of taking antiretroviral therapy (ΔeGFR − 2.3&#xa0;mL/min/1.73 m<sup>2</sup> per year), including 8&#xa0;years of tenofovir disoproxil fumarate (TDF) intake. After discontinuation of TDF and its successor drug, the eGFR stabilized at approximately 52 for approximately 4&#xa0;years. The SGLT2 inhibitor dapagliflozin was started to prevent renal decline. Subsequently, the eGFR increased to 57.3 after 3&#xa0;months and 60.2 after 6&#xa0;months, then was maintained at approximately 57 thereafter. After dapagliflozin initiation, the overall eGFR slope was + 1.2&#xa0;mL/min/1.73 m<sup>2</sup> per year. To the best of our knowledge, this was the first report demonstrating improvement in eGFR slope after SGLT2 inhibitor use in a patient with antiretroviral-associated renal impairment. This highlighted the potential role of SGLT2 inhibitors in mitigating CKD progression in people living with HIV.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Sustained eGFR improvement after dapagliflozin in a patient with antiretroviral therapy-related chronic kidney disease

  • 期刊论文

  • 发表日期：

    2025年8月8日

查看全文
  • Hirotaka Arae,
  • Shinichi Hoshino,
  • Nao Moromi,
  • Kouichi Tokumine,
  • Kentaro Kohagura

摘要

Chronic kidney disease (CKD) is an emerging concern in the aging population of people living with HIV, especially in those with history of nephrotoxic antiretroviral therapy. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown renoprotective effects in various clinical settings, but their utility in patients with antiretroviral-induced kidney impairment remains unexplored. We report the case of a 59-year-old man with well-controlled HIV infection who developed progressive decline in estimated glomerular filtration rate (eGFR, mL/min/1.73 m2) over 15 years of taking antiretroviral therapy (ΔeGFR − 2.3 mL/min/1.73 m2 per year), including 8 years of tenofovir disoproxil fumarate (TDF) intake. After discontinuation of TDF and its successor drug, the eGFR stabilized at approximately 52 for approximately 4 years. The SGLT2 inhibitor dapagliflozin was started to prevent renal decline. Subsequently, the eGFR increased to 57.3 after 3 months and 60.2 after 6 months, then was maintained at approximately 57 thereafter. After dapagliflozin initiation, the overall eGFR slope was + 1.2 mL/min/1.73 m2 per year. To the best of our knowledge, this was the first report demonstrating improvement in eGFR slope after SGLT2 inhibitor use in a patient with antiretroviral-associated renal impairment. This highlighted the potential role of SGLT2 inhibitors in mitigating CKD progression in people living with HIV.